Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Early Treatment with Ivermectin among Patients with Covid-19
Gilmar Reis, Eduardo A.S.M. Silva, Daniela C.M. Silva, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 18, pp. 1721-1731
Open Access | Times Cited: 200

Showing 1-25 of 200 citing articles:

Ivermectin for preventing and treating COVID-19
Maria Popp, Stefanie Reis, Selina Schießer, et al.
Cochrane library (2022) Vol. 2024, Iss. 3
Open Access | Times Cited: 153
Therapeutic advances in COVID-19
Naoka Murakami, Robert Hayden, Thomas Hills, et al.
Nature Reviews Nephrology (2022) Vol. 19, Iss. 1, pp. 38-52
Open Access | Times Cited: 123
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 111
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19
Susanna Naggie, David R. Boulware, Christopher J. Lindsell, et al.
JAMA (2022) Vol. 328, Iss. 16, pp. 1595-1595
Open Access | Times Cited: 76
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 75
Therapeutics for COVID-19
Sima S. Toussi, Jennifer Hammond, Brian S. Gerstenberger, et al.
Nature Microbiology (2023) Vol. 8, Iss. 5, pp. 771-786
Open Access | Times Cited: 65
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19
Susanna Naggie, David R. Boulware, Christopher J. Lindsell, et al.
JAMA (2023) Vol. 329, Iss. 11, pp. 888-888
Open Access | Times Cited: 48
Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19
Amy L. Lightner, Vikram Sengupta, Sascha Qian, et al.
CHEST Journal (2023) Vol. 164, Iss. 6, pp. 1444-1453
Open Access | Times Cited: 45
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
Viravarn Luvira, William Schilling, Podjanee Jittamala, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 14
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 59
Bioactive natural products in COVID-19 therapy
Zhonglei Wang, Ning Wang, Liyan Yang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 53
The potential role of ischaemia–reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications
Douglas B. Kell, Etheresia Pretorius
Biochemical Journal (2022) Vol. 479, Iss. 16, pp. 1653-1708
Open Access | Times Cited: 50
TheStaphylococcus aureusNetwork Adaptive Platform Trial Protocol: New Tools for an Old Foe
Steven Y. C. Tong, Jocelyn Mora, Asha C Bowen, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 11, pp. 2027-2034
Open Access | Times Cited: 48
Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial
James McMahon, Jillian S. Y. Lau, Anna Coldham, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101703-101703
Open Access | Times Cited: 39
Clinical course and management of COVID-19 in the era of widespread population immunity
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 28
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19
Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 5, pp. 667-675
Open Access | Times Cited: 27
Outpatient randomized controlled trials to reduce COVID‐19 hospitalization: Systematic review and meta‐analysis
David J. Sullivan, Daniele Focosi, Daniel F. Hanley, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Open Access | Times Cited: 19
Metformin: Past, Present, and Future
Sandeep Chaudhary, Amitabh Kulkarni
Current Diabetes Reports (2024) Vol. 24, Iss. 6, pp. 119-130
Closed Access | Times Cited: 11
Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review
Paula Andrea Cuartas Velásquez, Juan C. Hernández, Elkin Galeano, et al.
Clinical Pharmacology Advances and Applications (2024) Vol. Volume 16, pp. 1-25
Open Access | Times Cited: 9
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Gail Hayward, Ly‐Mee Yu, Paul Little, et al.
Journal of Infection (2024) Vol. 88, Iss. 4, pp. 106130-106130
Open Access | Times Cited: 9
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 8
Drug Repurposing in the Chemotherapy of Infectious Diseases
Amal Hamid, Pascal Mäser, Abdelhalim Babiker Mahmoud
Molecules (2024) Vol. 29, Iss. 3, pp. 635-635
Open Access | Times Cited: 6
Ivermectin as a Treatment Modality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Up-To-Date RCTs
Raghava Kalyan Maddukuri, Madhavi Latha Desimalla, Reshma Banavathu, et al.
Indian Journal of Community Medicine (2025) Vol. 50, Iss. 1, pp. 9-19
Open Access
Strategies for the Viral Exploitation of Nuclear Pore Transport Pathways
Xin Zhang, Keesiang Lim, Yujia Qiu, et al.
Viruses (2025) Vol. 17, Iss. 2, pp. 151-151
Open Access
Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype
Milena Soriano Marcolino, Karina Cardoso Meira, Nathália Sernizon Guimarães, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top